Weekly Policy Blog: Congratulations to CBSA’s 2023 Legislators of the Year
By: Colorado BioScience Association Date: 11/20/2023
On November 15, 2023, CBSA held its 20th Annual Awards Celebration presented by AGC Biologics. This annual celebration highlights the spirit and drive of Colorado’s vibrant life sciences ecosystem, br...
Learn MoreWeekly Policy Blog: Join CBSA in Asking Congress to Address the R&D Tax Now
By: Colorado BioScience Association Date: 11/13/2023
Join CBSA in asking Congress to support leading-edge health innovation by American life sciences companies. We are asking Congress to remove a “tax on innovation” by restoring the immediate expensing...
Learn MoreWeekly Policy Blog: Opposition to CMS’ Proposed Medicaid Drug Rebate Program (MDRP) Rule
By: Colorado BioScience Association Date: 11/06/2023
CBSA and other members of the Council of State Bioscience Associations (CSBA) have submitted a letter to the Centers for Medicare & Medicaid Services (CMS) expressing our deep concern with a recen...
Learn MoreWeekly Policy Blog: CBSA Has Concerns About Inconsistency of Preliminary Data Review Process for Drugs Under Affordability Review by PDAB
By: Colorado BioScience Association Date: 10/30/2023
CBSA has serious concerns about the Colorado Prescription Drug Affordability Board’s inconsistent approach to the preliminary data review process for drugs under affordability review in the first coho...
Learn MoreWeekly Policy Blog: USITC Report Released on TRIPS COVID-19 IP Waiver Expansion
By: Colorado BioScience Association Date: 10/23/2023
In June 2022, World Trade Organization (WTO) member states agreed to waive certain WTO intellectual property protections for COVID-19 vaccines. The U.S. Trade Representative (USTR) has been considerin...
Learn MoreWeekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders
By: Colorado BioScience Association Date: 10/16/2023
Weekly Policy Blog: CBSA Co-Hosts Facility Tours for State Legislators and Local Leaders This month CBSA partnered with both Terumo Blood and Cell Technologies (Terumo BCT) and AGC Biologics to host...
Learn MoreWeekly Policy Blog: CBSA Urges Congress to Pass the PASTEUR Act
By: Colorado BioScience Association Date: 09/25/2023
Earlier this month, CBSA participated in PASTEUR Advocacy Day, joining Biotechnology Innovation Organization (BIO) and other organizations, including Infectious Diseases Society of America, Cystic Fib...
Learn MoreEfforts to Control Prescription Drug Pricing Harm Collaborative Work to Advance Patient Care with Health Innovations
By: Colorado BioScience Association Date: 09/18/2023
Elyse Blazevich, President & CEO, Colorado BioScience Association Colorado’s life sciences community and our state leaders share an unwavering commitment to improving patient lives and making sure...
Learn MoreWeekly Policy Blog: FDA Guidances on 510(k) Submissions; Actuarial Review of Biomarker Testing Coverage Bill
By: Colorado BioScience Association Date: 09/11/2023
FDA Issues Three Guidances on Premarket Notification [510(k)] Program On September 7, 2023, the U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) issu...
Learn MoreWeekly Policy Blog: CMS Announces Drugs Subject to Price Controls Under the IRA
By: Colorado BioScience Association Date: 09/05/2023
On August 29, 2023, the Centers for Medicare and Medicaid Services (CMS) announced the first ten prescription drugs that will be subject to price controls in Medicare under the Inflation Reduction Act...
Learn More